AP2421A - Quinoline derivatives and their use as mycobacterial inhibitors. - Google Patents

Quinoline derivatives and their use as mycobacterial inhibitors.

Info

Publication number
AP2421A
AP2421A AP2005003210A AP2005003210A AP2421A AP 2421 A AP2421 A AP 2421A AP 2005003210 A AP2005003210 A AP 2005003210A AP 2005003210 A AP2005003210 A AP 2005003210A AP 2421 A AP2421 A AP 2421A
Authority
AP
ARIPO
Prior art keywords
quinoline derivatives
mycobacterial inhibitors
mycobacterial
inhibitors
quinoline
Prior art date
Application number
AP2005003210A
Other languages
English (en)
Other versions
AP2005003210A0 (en
Inventor
Jozef Frans Elisabeth Van Gestel
Jerome Emile Georges Guillemont
Marc Gaston Venet
Original Assignee
Janssen Pharmaceutica Nl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2421(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nl filed Critical Janssen Pharmaceutica Nl
Publication of AP2005003210A0 publication Critical patent/AP2005003210A0/xx
Application granted granted Critical
Publication of AP2421A publication Critical patent/AP2421A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AP2005003210A 2002-07-25 2003-07-18 Quinoline derivatives and their use as mycobacterial inhibitors. AP2421A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39871102P 2002-07-25 2002-07-25
PCT/EP2003/050322 WO2004011436A1 (en) 2002-07-25 2003-07-18 Quinoline derivatives and their use as mycobacterial inhibitors

Publications (2)

Publication Number Publication Date
AP2005003210A0 AP2005003210A0 (en) 2005-03-31
AP2421A true AP2421A (en) 2012-06-08

Family

ID=31188461

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2005003210A AP2421A (en) 2002-07-25 2003-07-18 Quinoline derivatives and their use as mycobacterial inhibitors.

Country Status (38)

Country Link
US (1) US7498343B2 (de)
EP (2) EP2301544B1 (de)
JP (1) JP4484703B2 (de)
KR (1) KR100733577B1 (de)
CN (2) CN1325475C (de)
AP (1) AP2421A (de)
AR (1) AR040673A1 (de)
AT (1) ATE463482T1 (de)
AU (1) AU2003262529B2 (de)
BE (1) BE2014C051I2 (de)
BR (1) BRPI0312927B8 (de)
CA (1) CA2493225C (de)
CY (3) CY1111882T1 (de)
DE (1) DE60332023D1 (de)
DK (2) DK2301544T3 (de)
EA (1) EA008937B1 (de)
ES (2) ES2343458T3 (de)
FR (1) FR14C0060I2 (de)
HK (2) HK1083496A1 (de)
HR (2) HRP20050045B1 (de)
HU (1) HUS1400047I1 (de)
IL (2) IL166457A (de)
IS (1) IS2914B (de)
LU (1) LU92520I2 (de)
ME (1) ME00131B (de)
MX (1) MXPA05001052A (de)
MY (1) MY143564A (de)
NL (1) NL300684I2 (de)
NO (2) NO329935B1 (de)
NZ (1) NZ538391A (de)
PL (1) PL222801B1 (de)
PT (2) PT1527050E (de)
RS (1) RS52431B (de)
SI (2) SI2301544T1 (de)
TW (1) TWI323730B (de)
UA (1) UA82198C2 (de)
WO (1) WO2004011436A1 (de)
ZA (1) ZA200500680B (de)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG166019A1 (en) * 2004-01-23 2010-11-29 Janssen Pharmaceutica Nv Quinoline derivatives and use thereof as mycobacterial inhibitors
ES2306082T3 (es) * 2004-01-23 2008-11-01 Janssen Pharmaceutica Nv Quinolinas sustituidas y su utilizacion como inhibidores micobacterianos.
KR101160183B1 (ko) * 2004-01-29 2012-06-26 얀센 파마슈티카 엔.브이. 마이코박테리아 저해제로서 사용하기 위한 퀴놀린 유도체
CN1976704B (zh) * 2004-05-28 2012-12-05 詹森药业有限公司 取代的喹啉衍生物在治疗耐药性分枝杆菌性疾病中的用途
KR101539021B1 (ko) * 2004-09-28 2015-07-23 얀센 파마슈티카 엔.브이. 박테리아 ａｔｐ 합성효소 결합 부분
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
JP2006182755A (ja) * 2004-12-24 2006-07-13 Janssen Pharmaceut Nv 潜伏性結核の処置
CA2606675C (en) * 2005-05-25 2013-02-19 Janssen Pharmaceutica N.V. Process for preparing (alpha s, beta r)-6-bromo-alpha-[2-(dimethylamino)ethyl]-2-methoxy-alpha-1-naphthalenyl-beta-phenyl-3-quinolineethanol
CA2528849C (en) 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
TWI380819B (zh) * 2005-06-08 2013-01-01 Janssen Pharmaceutica Nv 用作抗細菌劑之喹啉衍生物
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
KR101318181B1 (ko) * 2005-06-09 2013-10-16 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
WO2007000434A1 (en) * 2005-06-28 2007-01-04 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO3077B1 (ar) 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) * 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2685B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CN102249935B (zh) 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
CN104254528B (zh) 2012-04-27 2017-06-06 詹森药业有限公司 抗菌的喹啉衍生物
CN104254527B (zh) 2012-04-27 2017-05-31 詹森药业有限公司 抗菌的喹啉衍生物
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
PE20151165A1 (es) 2012-12-21 2015-08-19 Janssen Sciences Ireland Uc Derivados de benzazol como compuestos antibacteriales
RU2530493C1 (ru) * 2013-04-22 2014-10-10 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
JP6362235B2 (ja) * 2014-07-14 2018-07-25 ツーセン ファーマシューティカル カンパニー リミテッド ピリジン誘導体およびその抗マイコバクテリウムにおける使用
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105440051B (zh) * 2014-09-19 2019-07-05 重庆医药工业研究院有限责任公司 一种抗结核的噻吩吡啶衍生物
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
MX2017009681A (es) 2015-01-27 2017-10-18 Janssen Pharmaceutica Nv Composiciones dispersables.
EP3288386B1 (de) * 2015-04-29 2022-01-19 The State of Israel, Ministry of Agriculture & Rural Development, Agricultural Research Organization (ARO) (Volcani Center) Antiphytopathogene zusammensetzungen
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
CN108235704B (zh) 2015-07-02 2021-10-26 爱尔兰詹森科学公司 抗细菌化合物
CN105061387A (zh) * 2015-07-17 2015-11-18 苏州大学 二芳基醚类稠环类化合物、制备方法和用途
WO2017015793A1 (zh) * 2015-07-24 2017-02-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
KR102106318B1 (ko) 2015-10-20 2020-05-06 쯔지앙 하이썬 파머슈티컬 컴퍼니, 리미티드 베다퀼린 푸마레이트의 결정형 및 그의 제조방법
CN108473428B (zh) * 2016-01-13 2021-07-23 上海嘉坦医药科技有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
WO2017149551A1 (en) * 2016-03-03 2017-09-08 Council Of Scientific & Industrial Research Substituted aurone alkaloids as anti-mycobacterial agents
KR102355154B1 (ko) * 2016-03-07 2022-01-26 더 글로벌 얼라이언스 포 티비 드러그 디벨롭먼트, 잉크. 항박테리아 화합물 및 그의 용도
KR20190018681A (ko) 2016-06-16 2019-02-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균제로서의 헤테로고리 화합물
CN109476657A (zh) 2016-06-16 2019-03-15 爱尔兰詹森科学公司 作为抗细菌剂的杂环化合物
US11224596B2 (en) 2017-03-01 2022-01-18 Janssen Sciences Ireland Unlimited Company PZA and cytochrome bc1 inhibitor combination treatment
PL3651736T3 (pl) 2017-07-14 2021-12-20 Janssen Pharmaceutica Nv Formulacje o długotrwałym działaniu
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途
EP3908269A1 (de) 2019-01-09 2021-11-17 Janssen Pharmaceutica NV Kombination in der behandlung von nichttuberkulösen mykobakteriellen krankheiten
WO2020161743A1 (en) 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
US20220340564A1 (en) 2019-09-13 2022-10-27 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2021057190A1 (zh) * 2019-09-29 2021-04-01 上海阳帆医药科技有限公司 喹啉类化合物、其制备方法和用途
BR112022005449A2 (pt) 2019-09-30 2022-06-21 Janssen Sciences Ireland Unlimited Co Compostos antibacterianos
JP2022550784A (ja) 2019-09-30 2022-12-05 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー ４－キノリノン抗菌化合物
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
CN114867528B (zh) 2019-12-27 2024-03-19 社会医疗技术员技术股份公司 抗菌喹啉类
KR102303635B1 (ko) 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
US20240277614A1 (en) 2020-07-09 2024-08-22 Janssen Pharmaceutica Nv Long-acting formulations
CA3182425A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
US20230355606A1 (en) 2020-07-09 2023-11-09 Janssen Pharmaceutica Nv Long-acting formulations
CN116406270A (zh) 2020-11-12 2023-07-07 詹森药业有限公司 在治疗非结核分枝杆菌疾病时的贝达喹啉、乙胺丁醇和大环内酯的组合
CN117396475A (zh) 2021-03-16 2024-01-12 爱尔兰詹森科学公司 抗菌化合物
AU2022240967A1 (en) 2021-03-17 2023-11-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
MX2023010941A (es) 2021-03-17 2023-11-28 Janssen Sciences Ireland Unlimited Co Compuestos antibacterianos.
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
MX2024000111A (es) 2021-06-29 2024-01-19 Tecnimede Soc Tecnico Medicinal Sa Compuestos heterociclicos para el tratamiento de tuberculosis.
IL312366A (en) 2021-10-28 2024-06-01 Janssen Sciences Ireland Unlimited Co Imidazopyridine amides and related compounds for use in the treatment of bacterial infections
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN114835641B (zh) * 2022-05-07 2024-03-15 南京杰运医药科技有限公司 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法
CN117050006A (zh) * 2022-05-13 2023-11-14 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999037635A1 (en) * 1998-01-26 1999-07-29 Smithkline Beecham Plc Quinoline derivatives as antibacterials
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
WO2000034265A2 (en) * 1998-12-11 2000-06-15 Sepracor, Inc. Quinoline-indole antimicrobial agents

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010014030A (ko) * 1997-06-19 2001-02-26 더글라스이.리디치 퀴놀린-인돌 항균제, 이들의 용도 및 조성물
AU6645198A (en) * 1998-01-23 1999-08-09 Fire Armour Pte Ltd Nozzle with axially and perpendicularly directed apertures
US6819431B2 (en) * 2001-07-06 2004-11-16 Zygo Corporation Polymer retarder
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965572A (en) * 1996-10-28 1999-10-12 The United States Of America As Respresented By The Secretary Of The Army Methods for treating antibiotic-resistant infections
WO1999037635A1 (en) * 1998-01-26 1999-07-29 Smithkline Beecham Plc Quinoline derivatives as antibacterials
WO2000034265A2 (en) * 1998-12-11 2000-06-15 Sepracor, Inc. Quinoline-indole antimicrobial agents

Also Published As

Publication number Publication date
NL300684I2 (de) 2016-10-11
AR040673A1 (es) 2005-04-13
MY143564A (en) 2011-05-31
BRPI0312927B8 (pt) 2021-05-25
JP4484703B2 (ja) 2010-06-16
HK1113795A1 (en) 2008-10-17
RS20050058A (en) 2007-06-04
ES2343458T3 (es) 2010-08-02
HUS1400047I1 (hu) 2016-09-28
KR20050033607A (ko) 2005-04-12
CY2014033I2 (el) 2016-04-13
PL375523A1 (en) 2005-11-28
IL166457A0 (en) 2006-01-15
HRP20050045B1 (hr) 2013-09-30
EP2301544A1 (de) 2011-03-30
US7498343B2 (en) 2009-03-03
ME00131B (me) 2010-10-10
SI2301544T1 (sl) 2013-01-31
CN101070304B (zh) 2011-10-26
FR14C0060I1 (de) 2014-10-10
BRPI0312927B1 (pt) 2018-07-10
DK1527050T3 (da) 2010-07-19
KR100733577B1 (ko) 2007-06-29
CN1325475C (zh) 2007-07-11
TWI323730B (en) 2010-04-21
HRP20120190A2 (hr) 2012-05-31
HK1083496A1 (en) 2006-07-07
CN101070304A (zh) 2007-11-14
NZ538391A (en) 2005-10-28
CA2493225C (en) 2012-03-20
US20050148581A1 (en) 2005-07-07
ES2395237T3 (es) 2013-02-11
SI1527050T1 (sl) 2010-08-31
NO2014021I1 (no) 2014-08-20
IS7620A (is) 2004-12-29
HRP20120190A8 (en) 2012-07-31
IS2914B (is) 2014-12-15
LU92520I2 (fr) 2015-11-02
MXPA05001052A (es) 2005-04-08
PL222801B1 (pl) 2016-09-30
EA200500257A1 (ru) 2005-06-30
EP1527050B1 (de) 2010-04-07
NO20050476L (no) 2005-01-27
CN1671667A (zh) 2005-09-21
CY1113497T1 (el) 2016-06-22
ATE463482T1 (de) 2010-04-15
DE60332023D1 (de) 2010-05-20
IL166457A (en) 2011-10-31
PT1527050E (pt) 2010-06-22
NO329935B1 (no) 2011-01-24
IL202655A (en) 2012-04-30
CY1111882T1 (el) 2015-11-04
BE2014C051I2 (de) 2022-08-09
AP2005003210A0 (en) 2005-03-31
MEP9208A (en) 2010-06-10
CY2014033I1 (el) 2016-04-13
CA2493225A1 (en) 2004-02-05
NO2014021I2 (de) 2014-08-20
WO2004011436A1 (en) 2004-02-05
RS52431B (en) 2013-02-28
HRP20120190B1 (hr) 2017-06-02
PT2301544E (pt) 2012-12-10
FR14C0060I2 (fr) 2015-11-20
JP2006504658A (ja) 2006-02-09
AU2003262529A1 (en) 2004-02-16
TW200410939A (en) 2004-07-01
UA82198C2 (uk) 2008-03-25
EP2301544B1 (de) 2012-09-19
EP1527050A1 (de) 2005-05-04
BR0312927A (pt) 2005-07-12
HRP20050045A2 (en) 2006-06-30
ZA200500680B (en) 2006-08-30
AU2003262529B2 (en) 2009-11-19
EA008937B1 (ru) 2007-10-26
DK2301544T3 (da) 2013-01-02

Similar Documents

Publication Publication Date Title
AP2421A (en) Quinoline derivatives and their use as mycobacterial inhibitors.
AP2507A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors.
AP2188A (en) Substituted quinolines and their use as mycobacterial inhibitors.
HK1087699A1 (en) Gyrase inhibitors and uses thereof
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
EG24774A (en) Quinoline derivatives as phosphodiesterase inhibitors.
IL173986A0 (en) 2-pyridone derivatives as netrophil elastase inhibitors and their use
AU2003302919A1 (en) Pyridine derivatives as jnk inhibitors and their use
ZA200501677B (en) Hydantoin derivatives and their use as TACE inhibitors.
ZA200410054B (en) Propionic acid derivatives and their use as hPPARsactivators.
AU2003232848A1 (en) Phenylaminopyrimidines and their use as rho-kinase inhibitors
AU2003269421A8 (en) Hiv-integrase inhibitors, pharmaceutical compositions, and methods for their use
AU2003215756A1 (en) Benzimidazoles and their use as mitogen-activated- and rho-kinase inhibitors
PL374581A1 (en) Diaminothiazoles and use thereof as cdk4 inhibitors
HK1071364A1 (en) Quinoline derivatives
AU2003258942A1 (en) Imidazolidinedione-derivatives and their use as metalloproteinase inhibitors
AU2003218715A1 (en) Azepane derivatives and their use as atk1 inhibitors
GB0511267D0 (en) Indol derivatives and their use as kinase inhibitors
AU2003262008A1 (en) Polynucleotide derivative and use thereof